Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
Holders of 5% or more of RXRX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Recursion Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 7.25%37.3M shares | −1.22 ppfrom 8.47% | Feb 14, 20252 filings | Feb 3, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.20%37.8M shares | +1.10 ppfrom 6.10% | Feb 5, 20252 filings | Apr 24, 2026 | SEC |
| Baillie Gifford & Co | 13G/A | 6.50%24.9M shares | −2.70 ppfrom 9.20% | Nov 4, 20242 filings | Feb 12, 2025 | SEC |
| State Street Corp | 13G | 5.50%28.5M shares | New | May 12, 20261 filing | May 12, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
11 Schedule 13D and 13G filings on Recursion Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 12, 202611:53 AM ET | State Street Corp | 13G | 5.50%28.5M shares | New | Mar 31, 2026 | SEC |
| Apr 24, 20264:11 PM ET | BlackRock, Inc. | 13G/A | 7.20%37.8M shares | +1.10 ppfrom 6.10% | Mar 31, 2026 | SEC |
| Mar 27, 202611:36 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 5, 202610:04 AM ET | Baillie Gifford & Co | 13G/A | 4.60%23.8M shares | –Below 5% | Dec 31, 2025 | SEC |
| Feb 3, 202611:38 AM ET | ARK Investment Management LLCand 1 otherSuperinvestorARK Invest | 13G/A | 7.25%37.3M shares | −1.22 ppfrom 8.47% | Dec 31, 2025 | SEC |
| Dec 23, 20257:25 PM ET | Mubadala Investment Co PJSCand 6 others | 13D/A | 1.40%7.06M shares | –Below 5% | Nov 20, 2024 | SEC |
| Feb 14, 20256:41 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 2.00%7.73M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 202511:23 AM ET | ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 8.47%32.3M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:32 AM ET | Baillie Gifford & Co | 13G/A | 6.50%24.9M shares | −2.70 ppfrom 9.20% | Dec 31, 2024 | SEC |
| Feb 5, 20255:28 PM ET | BlackRock, Inc. | 13G/A | 6.10%23.4M shares | – | Dec 31, 2024 | SEC |
| Nov 4, 20249:46 AM ET | Baillie Gifford & Co | 13G/A | 9.20%25.2M shares | – | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Recursion Pharmaceuticals, Inc. shares.
No Form 144 notices for Recursion Pharmaceuticals, Inc. are on file.